Arialief: We Tested It—Here’s Our Honest Arialief Review “Shocking Conclusion”
Is Arialief the breakthrough for nerve pain, numbness, and tingling through full-spectrum metabolic support? Read our real Arialief review and...
Brain
Prime Biome: We Tested It—Here’s My Honest Prime Biome Review After 117 Days!
Is Prime Biome’s “gut-skin synergy” the secret to beating bloating, revealing clearer skin, and maintaining steady weight management? Explore real...
NervGen Pharma Reports 2024 Year-End Financial Results and Provides Business Updates
Completed enrollment in the chronic cohort and commenced enrollment in the subacute cohort of its Phase 1b/2a clinical trial for...
PreveCeutical Announces Update to Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - April 2, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company"...
Zeto Unveils NeuroPulse, the First AI-Powered Status Epilepticus Software Using Full 10-20 EEG in Collaboration with encevis
SANTA CLARA, Calif., April 2, 2025 /PRNewswire/ -- Zeto, Inc., a fast-growing medical technology company revolutionizing EEG diagnostics with its...
Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial
HOUSTON, TX, April 02, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader...
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma
JERUSALEM, April 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation...
FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair
HOUSTON, April 02, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued...
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program
Rolling submission of BLA initiated for tividenofusp alfa; preparations ongoing for potential U.S. commercial launch in late 2025 or early...
Experience Onward Partners with Enthea to Expand Access to Psilocybin Treatment Through a Medical Tourism Benefit
Portland, Oregon--(Newsfile Corp. - April 2, 2025) - Experience Onward, Oregon's premier state-licensed psilocybin service center, is proud to announce...
Wellform MD is first in Iowa to Offer Leading-edge Technology Using Brain Stimulation to Treat Depression
Complimentary Launch Party April 24 to Showcase New Procedure ANKENY, Iowa, April 1, 2025 /PRNewswire/ -- Wellform MD, Des Moine's...
Leading Mental Health Provider SonderMind Expands Nationwide, Delivering High-Quality Mental Health Care in All 50 States
DENVER, April 1, 2025 /PRNewswire/ -- SonderMind, a leader in comprehensive, personalized mental health care, announced it is now serving...
Preventing Underage Drinking Starts at Home: Talk It Out NC Empowers Parents and Children to Take Action Against Underage Drinking
Alcohol Awareness Month Highlights the Importance of Open Dialogue to Prevent Underage Drinking RALEIGH, N.C., April 1, 2025 /PRNewswire/ -- Talk...
REMINDER: Microbot Medical Announces Data from the Company’s ACCESS-PVI trial will be Presented via Podium Presentation at Society of Interventional Radiology Annual Meeting
Company Reaffirms Expected Timing of FDA Decision With Respect to 510(K) Clearance of LIBERTY® During the Current Second QuarterBRAINTREE, Mass.,...
Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial
– Initial data readout on track for second half of 2025 HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech,...
Cerevance Presents Topline Results from Phase 2 ASCEND Trial of Solengepras as Monotherapy Treatment for Early-Stage Parkinson’s Disease at AD/PD 2025
Solengepras showed evidence of potential benefit in functional and non-motor symptoms versus placebo as measured by MDS-UPRDS Parts I, II,...
Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients
Data published in Neuro-Oncology demonstrate promising safety profile and potential survival benefit when combining CAN-2409 and nivolumab with standard of...
Prime Biome Reviews [DOCTOR INVESTIGATION TRUTH]: The Revolutionary Supplement Transforming Gut Health & Wellness
ORLANDO, Fla., March 31, 2025 (GLOBE NEWSWIRE) -- The pioneering solution Prime Biome provides USA residents with a way to...
Next Health and Sunlife Organics Partner on “Limitless” Superfood Smoothie to Optimize Health through Nutrition
LOS ANGELES--(BUSINESS WIRE)--#biohacking--Next Health, the world’s most advanced and comprehensive brand of health optimization and longevity centers, has teamed up...
ProDentim Reviews (EXPOSED): Why 75,000+ Americans Are Replacing Mouthwash with This ProDentim Chewable Tablet
Discover the Oral Probiotic That’s Reshaping Dental Health—Backed by 75,000+ Users and Groundbreaking Science ProDentim reviews ProDentim Official VANCOUVER, WA,...